CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the closing of its previously announced public offering of 3,739,130 units at the public offering price of $5.75 per unit. Each unit consisted of one share of common stock and six-tenths (0.6) of a warrant to purchase one share of common stock with an exercise price of $6.60 per share.
Cowen and Company and Stifel acted as joint book-running managers for the offering. JMP Securities acted as lead manager and Oppenheimer & Co. acted as co-manager for the offering.
Help employers find you! Check out all the jobs and post your resume.
Cowen and Company and Stifel acted as joint book-running managers for the offering. JMP Securities acted as lead manager and Oppenheimer & Co. acted as co-manager for the offering.
Help employers find you! Check out all the jobs and post your resume.
